Posts by DCprime


HomeDCprime

Jeroen Rovers MD, PhD joins DCprime as Chief Medical Officer

Leiden, The Netherlands, October 01, 2018 – DCprime announces today that Jeroen Rovers MD, PhD joins the company as its Chief Medical Officer with immediate effect. Jeroen trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 15 years he worked in different academic institutes and companies, lastly


DCprime and Glycotope announce licensing agreement and collaboration

    DCprime and Glycotope announce licensing agreement and collaboration Leiden, The Netherlands, and Berlin, Germany, 18 July 2018 – DCprime bv, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, announce today that they have entered into a license agreement


DCprime announces that Erik Manting PhD will join the company as its CEO

Leiden, The Netherlands, March 01, 2018 – DCprime announces today that Erik Manting PhD will become DCprime’s new Chief Executive Officer with immediate effect. Dr Manting succeeds Ada Kruisbeek, who will remain committed to DCprime as Chief Scientific Officer. Prior to joining DCprime, Erik spent 15 years in different management and commercial roles, of which


DCOne® induces immune responses against Multiple Myeloma

Leiden, The Netherlands – DCPrime B.V., a clinical stage company dedicated to developing cancer vaccines based on its proprietary DCOne® platform, announces the publication of a peer-reviewed research paper which documents that its lead product DCP-001 can induce T cell activation and myeloma-specific immunity in peripheral blood mononuclear cells from patients with Multiple Myeloma (MM).


DCPrime and apceth Biopharma GmbH announce manufacturing partnership

Leiden, The Netherlands, and Munich, Germany – DCPrime BV, a clinical stage company developing dendritic cell vaccines to treat cancer, and apceth Biopharma GmbH, an established contract manufacturing organization in the field of gene and cell therapy, report today that they have entered into a strategic manufacturing agreement. The collaboration involves clinical batch production and


DCPrime obtains patent protection for DCOne® platform

DCPrime obtains broad patent protection in the EU for proprietary DCOne® platform. DCPrime, a clinical stage cancer immunotherapy company, has been granted a European patent on its DCOne® platform. The patent covers its proprietary cell line DCOne®, the accompanying methods for obtaining mature dendritic cells, and the mature dendritic cells which are obtainable by this method,


DCPrime and VUmc awarded €6 million Euro Horizon2020 grant

DCPrime and VUmc awarded Horizon2020 grant to support the development of a dendritic-cell vaccine therapy for Acute Myeloid Leukemia. DCPrime, a Dutch cancer immunotherapy company, and the Department of Hematology of the VU medical center in Amsterdam, announce that, together with a strong international consortium of academic and company partners, they have been awarded a 6


DCPrime and Dana Farber Cancer Center start collaboration on cancer immunotherapy treatment of Multiple Myeloma

Leiden, The Netherlands – Dutch clinical stage company DCPrime BV, dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne®, today announced that it has started a collaboration on the potential application of its lead product DCP-001 in Multiple Myeloma patients with Prof. Dr. David Avigan, Beth Israel Deaconess Medical Center, Dana